Nuformix PLC
1RT
Company Profile
Business description
Nuformix PLC is a pharmaceutical development company. It operates in the field of pharmaceutical development targeting unmet medical needs in fibrosis and oncology via drug repurposing. Its pipeline products include NXP001, NXP002, and NXP004. Geographically, the company operates only in the UK.
Contact
60 Gracechurch Street
6th Floor
LondonEC3V 0HR
GBRT: +44 1223627222
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 September 2026
Employees
3
Stocks News & Analysis
stocks
Is this ASX share a value trap or bargain?
Cost-cutting the priority as underlying asset values falling on deaf ears.
stocks
Goldman Sachs Earnings: Valuations remain stretched
We raise our fair value estimate for Goldman Sachs stock.
stocks
Major ASX listed miners overvalued
We’ve adjusted our fair values after updating our commodity price assumptions.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,138.60 | 19.70 | -0.22% |
| CAC 40 | 8,021.22 | 90.80 | -1.12% |
| DAX 40 | 24,606.64 | 352.42 | -1.41% |
| Dow JONES (US) | 49,359.33 | 83.11 | -0.17% |
| FTSE 100 | 10,083.69 | 111.66 | -1.10% |
| HKSE | 26,487.51 | 76.39 | -0.29% |
| NASDAQ | 23,515.39 | 14.63 | -0.06% |
| Nikkei 225 | 52,991.10 | 592.47 | -1.11% |
| NZX 50 Index | 13,573.93 | 6.36 | -0.05% |
| S&P 500 | 6,940.01 | 0.00 | 0.00% |
| S&P/ASX 200 | 8,815.90 | 20.70 | -0.23% |
| SSE Composite Index | 4,113.65 | 0.35 | -0.01% |